An interventional study of Titanium framework reinforced all on four prosthesis and PEEK framework reinforced all on four prosthesis in Prosthodontics, Implants, Dental and Prosthesis, sponsored by Cairo University. Active, not recruiting at 1 site in Egypt. Open to participants aged 45 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Alveolar Bone Loss by Cairo University — 10 open to participants now, 11 under way, none of them phase 3. Alveolar Bone Loss · Cairo University.
Among the 30 studies in Alveolar Bone Loss by Cairo University, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is one of 29 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 26th registered.
320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
Browse Alveolar Bone Loss studies →10 of the 30 studies in Alveolar Bone Loss by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 20–60
Cairo University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18+ · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.
This study: 45 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 6 started in 2024.
This study's enrollment of 20 is below the median of 25 across 271 interventional studies indexed under Alveolar Bone Loss.
Median enrollment 20 across the 30 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Alveolar Bone Loss by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475507Cairo UniversityEffect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles | 2026-12 |
| NCT07701473Cairo UniversityNovel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Alveolar Bone Loss by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A fixed all-on-four prosthesis will be constructed for the lower arch for each patient and the marginal bone loss will be evaluated at baseline, 3,6,9 and 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with no systemic condition that may interfere with implant placement (e.g., or immunocompromised patients, patients under treatment of intravenous amino-bisphosphonates)
-
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Comparator: Titanium reinforced fixed all-on-four prosthesis
Other: Titanium framework reinforced all on four prosthesis
Other: PEEK framework reinforced all on four prosthesis
Titanium frameworks provided many advantages as their biocompatibility, corrosion resistance, relatively lower weight and high mechanical properties as well as avoiding the casting errors and technique sensitivity
Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK
Marginal bone loss
Marginal bone loss around each dental implant using parallel technique in digital periodical radiographs which will be measured in mm from the crestal bone level at the implant platform.
Time frame: 12 months at intervals (0,3,6,9and 12 months)
Bone density
Bone density around dental implants will be measured using digora digital radiographs which will be measured in hounsfield units.
Time frame: 12 months at intervals (0,3,6,9and 12 months)
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 28 months is above that.
Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.